CL2013002007A1 - Compuesto polimorfo (s)-3-(1-(9h-purin-6-ilamino)etil)-8-cloro-2-fenilisoquinolin-1-(2h)-ona de formas b-j, amorfa, sal, solvato o hidrato del mismo; mezclas de estos compuestos; metodo para preparar el polimorfo de forma c; composicion farmaceutica; metodo de tratamiento; uso para el tratamiento de un trastorno mediado por pi3k. - Google Patents

Compuesto polimorfo (s)-3-(1-(9h-purin-6-ilamino)etil)-8-cloro-2-fenilisoquinolin-1-(2h)-ona de formas b-j, amorfa, sal, solvato o hidrato del mismo; mezclas de estos compuestos; metodo para preparar el polimorfo de forma c; composicion farmaceutica; metodo de tratamiento; uso para el tratamiento de un trastorno mediado por pi3k.

Info

Publication number: CL2013002007A1
Authority: CL; Chile
Prior art keywords: polymorph; treatment; phenylisoquinolin; purin; pi3k
Prior art date: 2011-01-10

Application number

CL2013002007A

Other languages

English (en)

Inventor

Pingda Ren

Michael Martin

Paul Isbester

Benjamin S Lane

Jason Kropp

Original Assignee

Infinity Pharmaceuticals Inc

Intellikine Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-10

Filing date

2013-07-09

Publication date

2014-04-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46491229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002007(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-09 Application filed by Infinity Pharmaceuticals Inc, Intellikine Inc filed Critical Infinity Pharmaceuticals Inc

2014-04-11 Publication of CL2013002007A1 publication Critical patent/CL2013002007A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2013002007A 2011-01-10 2013-07-09 Compuesto polimorfo (s)-3-(1-(9h-purin-6-ilamino)etil)-8-cloro-2-fenilisoquinolin-1-(2h)-ona de formas b-j, amorfa, sal, solvato o hidrato del mismo; mezclas de estos compuestos; metodo para preparar el polimorfo de forma c; composicion farmaceutica; metodo de tratamiento; uso para el tratamiento de un trastorno mediado por pi3k. CL2013002007A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161431304P	2011-01-10	2011-01-10
US201161578655P	2011-12-21	2011-12-21

Publications (1)

Publication Number	Publication Date
CL2013002007A1 true CL2013002007A1 (es)	2014-04-11

Family

ID=46491229

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013002007A CL2013002007A1 (es)	2011-01-10	2013-07-09	Compuesto polimorfo (s)-3-(1-(9h-purin-6-ilamino)etil)-8-cloro-2-fenilisoquinolin-1-(2h)-ona de formas b-j, amorfa, sal, solvato o hidrato del mismo; mezclas de estos compuestos; metodo para preparar el polimorfo de forma c; composicion farmaceutica; metodo de tratamiento; uso para el tratamiento de un trastorno mediado por pi3k.

Country Status (23)

Country	Link
US (8)	US8809349B2 (es)
EP (3)	EP2663309B1 (es)
JP (2)	JP2014501790A (es)
KR (2)	KR101875720B1 (es)
CN (1)	CN103648499B (es)
AR (1)	AR084824A1 (es)
AU (1)	AU2012205669B2 (es)
BR (1)	BR112013017670B1 (es)
CA (1)	CA2824197C (es)
CL (1)	CL2013002007A1 (es)
DK (1)	DK2663309T3 (es)
ES (1)	ES2637113T3 (es)
HK (1)	HK1245110B (es)
IL (1)	IL227387B (es)
MX (1)	MX347708B (es)
NZ (1)	NZ612909A (es)
PE (2)	PE20180318A1 (es)
PH (2)	PH12013501465A1 (es)
SG (2)	SG191897A1 (es)
TW (3)	TWI659956B (es)
UA (1)	UA115767C2 (es)
WO (1)	WO2012097000A1 (es)
ZA (1)	ZA201305150B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1583562E (pt)	2003-01-06	2011-09-19	Angiochem Inc	Angiopep-1, compostos relacionados, e suas utilizações
US9365634B2 (en)	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204487C1 (en)	2008-01-04	2014-10-16	Intellikine, Llc	Certain chemical entities, compositions and methods
TR201905480T4 (tr)	2008-04-18	2019-05-21	Angiochem Inc	Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
EP2346508B1 (en)	2008-09-26	2016-08-24	Intellikine, LLC	Heterocyclic kinase inhibitors
EP2346906A4 (en)	2008-10-15	2013-04-24	Angiochem Inc	CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
EP2346896A4 (en)	2008-10-15	2014-06-25	Angiochem Inc	ETOPOSID AND DOXORUBICIN CONJUGATES FOR ACTIVITY EXTRACTION
US9914754B2 (en)	2008-12-05	2018-03-13	Angiochem Inc.	Conjugates of neurotensin or neurotensin analogs and uses thereof
CN102292338B (zh)	2008-12-08	2016-09-28	萌蒂制药国际有限公司	酪氨酸激酶蛋白受体拮抗剂
EP2373789A4 (en)	2008-12-17	2012-08-29	Angiochem Inc	MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
ES2729261T3 (es)	2009-04-20	2019-10-31	Angiochem Inc	Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
CA2760791C (en)	2009-05-07	2017-06-20	Intellikine, Inc.	Heterocyclic compounds and uses thereof
US8940752B2 (en)	2009-06-29	2015-01-27	Incyte Corporation	Pyrimidinones as PI3K inhibitors
EP2448965A4 (en)	2009-07-02	2015-02-11	Angiochem Inc	MULTIMEPEPTID CONJUGATES AND ITS USES
WO2011075643A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted heteroaryl fused derivatives as pi3k inhibitors
AR081823A1 (es)	2010-04-14	2012-10-24	Incyte Corp	DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
ES2593256T3 (es)	2010-05-21	2016-12-07	Infinity Pharmaceuticals, Inc.	Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
US8901133B2 (en)	2010-11-10	2014-12-02	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
AR084366A1 (es)	2010-12-20	2013-05-08	Incyte Corp	N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
CN103648499B (zh)	2011-01-10	2017-02-15	无限药品股份有限公司	用于制备异喹啉酮的方法及异喹啉酮的固体形式
US9108984B2 (en)	2011-03-14	2015-08-18	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en)	2011-03-25	2012-10-04	Incyte Corporation	Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AU2012284091B2 (en)	2011-07-19	2015-11-12	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
HK1198443A1 (en)	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
KR20140079368A (ko) *	2011-08-11	2014-06-26	인텔리카인, 엘엘씨	키나아제 억제제 다형체
EP2751093A1 (en)	2011-08-29	2014-07-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR102030609B1 (ko)	2011-09-02	2019-10-11	인사이트 홀딩스 코포레이션	Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
CA2857302C (en)	2011-12-15	2020-08-25	Novartis Ag	Use of inhibitors of the activity or function of pi3k
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en) *	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN102850271A (zh) *	2012-09-10	2013-01-02	盛世泰科生物医药技术(苏州)有限公司	3-(1-氨乙基)-2-环丁基-2-氢-异喹啉-1-酮类化合物的合成
US20140120060A1 (en)	2012-11-01	2014-05-01	Infinity Pharmaceuticals, Inc.	Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
SI2914296T2 (sl)	2012-11-01	2022-01-31	Infinity Pharmaceuticals, Inc.	Zdravljenje raznih vrst raka z uporabo modulatorjev izooblik PI3-kinaze
JP6434416B2 (ja)	2012-11-08	2018-12-05	ライゼン・ファーマシューティカルズ・エスアー	ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
US9029384B2 (en)	2012-12-21	2015-05-12	Gilead Calistoga, LLC.	Phosphatidylinositol 3-kinase inhibitors
WO2014100765A1 (en)	2012-12-21	2014-06-26	Gilead Calistoga Llc	Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
US11407721B2 (en)	2013-02-19	2022-08-09	Amgen Inc.	CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US8999992B2 (en)	2013-03-15	2015-04-07	Vm Pharma Llc	Crystalline forms of tryosine kinase inhibitors and their salts
RU2705204C2 (ru) *	2013-05-30	2019-11-06	Инфинити Фармасьютикалз, Инк.	Лечение злокачественных опухолей с использованием модуляторов изоформ piз-киназы
JOP20200296A1 (ar) *	2013-06-10	2017-06-16	Amgen Inc	عمليات صنع وأشكال بلورية من mdm2 مثبط
EA028319B1 (ru)	2013-06-14	2017-11-30	Джилид Калистога Ллс	Ингибиторы фосфатидилинозитол-3-киназы
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
TWI657085B (zh)	2013-10-04	2019-04-21	英菲尼提製藥股份有限公司	雜環化合物及其用途
US20160244452A1 (en) *	2013-10-21	2016-08-25	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20160093062A (ko)	2013-12-05	2016-08-05	아세르타 파마. 비.브이.	Pi3k 억제제 및 btk 억제제의 치료적 조합
CN104817559B (zh)	2014-01-30	2021-05-25	苏州泽璟生物制药股份有限公司	氘代喹唑啉酮化合物以及包含该化合物的药物组合物
US9775844B2 (en)	2014-03-19	2017-10-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2015160986A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2015191677A1 (en)	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI705814B (zh) *	2014-06-20	2020-10-01	美商梅琳塔有限責任公司	醫藥組成物及其用途
BR112017000132A2 (en)	2014-07-04	2018-01-09	Lupin Limited	compound, pharmaceutical composition and method of treating or preventing a disease responsive to inhibition of pi3k activity
SMT202200285T1 (it)	2014-08-11	2022-09-14	Acerta Pharma Bv	Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
ES2900184T3 (es)	2014-08-11	2022-03-16	Acerta Pharma Bv	Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
TW201618773A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
JP6559775B2 (ja)	2014-09-03	2019-08-14	ライゼン・ファーマシューティカルズ・エスアー	二重ｐｉ３ｋデルタ‐ガンマキナーゼ阻害剤及びコルチコステロイドを含む治療方法及び組成物
CA2962206A1 (en) *	2014-09-17	2016-03-24	Mundipharma International Corporation Limited	Crystalline forms of tyrosine kinase inhibitors and their salts
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016127844A1 (zh) *	2015-02-12	2016-08-18	苏州晶云药物科技有限公司	IPI-145的晶型α及其制备方法
DK3831833T3 (da)	2015-02-27	2022-11-14	Incyte Holdings Corp	Fremgangsmåder til fremstillingen af en pi3k-inhibitor
US9732097B2 (en)	2015-05-11	2017-08-15	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Crystalline forms of a pi3k inhibitor
CN107921143B (zh)	2015-06-15	2021-11-19	安吉奥开米公司	用于治疗软脑膜癌病的方法
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2017223422A1 (en)	2016-06-24	2017-12-28	Infinity Pharmaceuticals, Inc.	Combination therapies
BR112020002736A2 (pt) *	2017-08-09	2020-07-28	Prelude Therapeutics, Incorporated	inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
WO2019064066A1 (en) *	2017-09-27	2019-04-04	F. Hoffmann-La Roche Ag	PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
KR102363043B1 (ko) *	2018-01-12	2022-02-15	보령제약 주식회사	Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP7407740B2 (ja)	2018-05-18	2024-01-04	ノバルティスアーゲー	Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
WO2019232223A1 (en)	2018-05-30	2019-12-05	University Of Notre Dame Du Lac	Hsp90 beta selective inhibitors
IL278889B2 (en)	2018-06-01	2025-11-01	Incyte Corp	Dosing regimen for the treatment of pi3k related disorders
CN108982465B (zh) *	2018-06-06	2020-10-02	上海应用技术大学	酒中二氧化硫高通量sers在线检测方法
CN109364601B (zh) *	2018-12-21	2021-05-28	山东京博众诚清洁能源有限公司	一种炼厂废气的处理方法
KR20200129704A (ko) *	2019-05-09	2020-11-18	보령제약 주식회사	Pi3k 저해제의 결정다형 및 이의 제조방법
KR20200129705A (ko) *	2019-05-09	2020-11-18	보령제약 주식회사	무정형의 pi3k 저해제 및 이를 포함하는 약학적 조성물
KR102338609B1 (ko) *	2019-05-20	2021-12-14	보령제약 주식회사	피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물
GB201915447D0 (en) *	2019-10-24	2019-12-11	Johnson Matthey Plc	Polymorphs of avapritinib and methods of preparing the polymorphs
CN115279339A (zh) *	2020-01-10	2022-11-01	美国安进公司	稳定的无环糊精的卡非佐米配制品
CN111635404B (zh) *	2020-07-17	2023-11-07	苏州明锐医药科技有限公司	一种度维尼西的制备方法
CN111675710B (zh) *	2020-07-17	2023-08-18	上海奥萝拉医药科技有限公司	度维尼西的制备方法
WO2022044040A1 (en) *	2020-08-25	2022-03-03	Msn Laboratories Private Limited, R&D Center	Novel polymorphs of (s)-3-(1-(9h-purin-6-yl-amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2h)-one
CN112595691B (zh) *	2020-11-16	2024-09-27	伊犁紫苏丽人生物科技有限公司	基于近红外拉曼光谱融合的薰衣草精油特征组分定量分析模型的建立方法和定量分析方法
CN112410355B (zh) *	2020-11-23	2022-03-25	昆明理工大学	一种酰基辅酶a氧化酶2基因rkacox2及其应用
EP4356114A4 (en) *	2021-06-18	2025-05-14	Polyvalor, Limited Partnership	Methods and systems for interrogating a saliva droplet using Raman spectroscopy
EP4436581A4 (en) *	2021-11-22	2025-08-13	Secura Bio Inc	METHODS OF TREATING PERIPHERAL T-CELL LYMPHOMA
WO2024163039A1 (en)	2023-01-30	2024-08-08	The Trustees Of Princeton University	Cancer treatment using pi3k inhibitors in combination with antibiotics or purified diets
EP4676484A1 (en) *	2023-03-09	2026-01-14	BDR Pharmaceuticals International Private Limited	Solid oral composition of olaparib and its salts thereof
CN118388485B (zh) *	2024-05-16	2024-11-05	江苏海洋大学	一种杜韦利西布的合成方法

Family Cites Families (671)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB812366A (en)	1955-08-18	1959-04-22	Wellcome Found	Improvements in and relating to derivatives of pyrimidine and the preparation thereof
GB937725A (en)	1960-05-11	1963-09-25	Ciba Ltd	Pyrazolo[3:4-d]pyrimidines
JPS4834699B1 (es)	1968-07-03	1973-10-23
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3657744A (en)	1970-05-08	1972-04-25	Univ Minnesota	Method for fixing prosthetic implants in a living body
DE2139107A1 (de)	1971-08-04	1973-02-15	Merck Patent Gmbh	Heterocyclisch substituierte adenosinverbindungen
JPS4834699A (es)	1971-09-08	1973-05-21
JPS5148231B2 (es)	1971-10-20	1976-12-20
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4270537A (en)	1979-11-19	1981-06-02	Romaine Richard A	Automatic hypodermic syringe
IT1153216B (it)	1981-10-16	1987-01-14	Schering Ag	Procedimento per la preparazione di composti cianoeterociclici
DE3244594A1 (de)	1982-12-02	1984-06-07	Hoechst Ag, 6230 Frankfurt	1-phenylisochinolinderivate und verfahren zu ihrer herstellung, diese verbindung enthaltende pharmazeutische praeparate und deren anwendung
DE3406533A1 (de)	1984-02-23	1985-08-29	Boehringer Mannheim Gmbh, 6800 Mannheim	Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US5310731A (en)	1984-06-28	1994-05-10	Whitby Research, Inc.	N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
KR890002631B1 (ko)	1984-10-04	1989-07-21	몬산토 캄파니	생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US4795627A (en)	1984-10-18	1989-01-03	University Of Pittsburgh	Tritium labelled N-mustard type compounds and a process for their production
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4656159A (en)	1984-10-31	1987-04-07	Georgetown University	Galactose-C-6 nitrogen mustard compounds and their uses
JPS61109797A (ja)	1984-11-01	1986-05-28	Yuki Gosei Yakuhin Kogyo Kk	標識化ヌクレオチドおよび標識化ポリヌクレオチド
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US4733665C2 (en)	1985-11-07	2002-01-29	Expandable Grafts Partnership	Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5061273A (en)	1989-06-01	1991-10-29	Yock Paul G	Angioplasty apparatus facilitating rapid exchanges
US5040548A (en)	1989-06-01	1991-08-20	Yock Paul G	Angioplasty mehtod
US5350395A (en)	1986-04-15	1994-09-27	Yock Paul G	Angioplasty apparatus facilitating rapid exchanges
US4886499A (en)	1986-12-18	1989-12-12	Hoffmann-La Roche Inc.	Portable injection appliance
US4748982A (en)	1987-01-06	1988-06-07	Advanced Cardiovascular Systems, Inc.	Reinforced balloon dilatation catheter with slitted exchange sleeve and method
GB8704027D0 (en)	1987-02-20	1987-03-25	Owen Mumford Ltd	Syringe needle combination
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4940460A (en)	1987-06-19	1990-07-10	Bioject, Inc.	Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en)	1988-03-16	1994-08-16	Canon Kabushiki Kaisha	Automatic exposure control device using plural image plane detection areas
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
WO1990003370A1 (en)	1988-09-28	1990-04-05	Microprobe Corporation	DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
CA1322628C (en)	1988-10-04	1993-10-05	Richard A. Schatz	Expandable intraluminal graft
FR2638359A1 (fr)	1988-11-03	1990-05-04	Tino Dalto	Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en)	1989-07-07	1997-12-23	Novartis Inc	Sustained release formulations of water soluble peptides.
US5428125A (en)	1989-07-17	1995-06-27	The Dow Chemical Company	Mesogenic polycyanates and thermosets thereof
US5442039A (en)	1989-07-17	1995-08-15	The Dow Chemical Company	Mesogenic polycyanates and thermosets thereof
US6344053B1 (en)	1993-12-22	2002-02-05	Medtronic Ave, Inc.	Endovascular support device and method
US5292331A (en)	1989-08-24	1994-03-08	Applied Vascular Engineering, Inc.	Endovascular support device
US5674278A (en)	1989-08-24	1997-10-07	Arterial Vascular Engineering, Inc.	Endovascular support device
US5674998A (en)	1989-09-15	1997-10-07	Gensia Inc.	C-4' modified adenosine kinase inhibitors
US5646128A (en)	1989-09-15	1997-07-08	Gensia, Inc.	Methods for treating adenosine kinase related conditions
US5763597A (en)	1989-09-15	1998-06-09	Metabasis Therapeutics, Inc.	Orally active adenosine kinase inhibitors
US5721356A (en)	1989-09-15	1998-02-24	Gensia, Inc.	Orally active adenosine kinase inhibitors
US5795977A (en)	1989-09-15	1998-08-18	Metabasis Therapeutics, Inc.	Water soluble adenosine kinase inhibitors
US5763596A (en)	1989-09-15	1998-06-09	Metabasis Therapeutics, Inc.	C-4' modified adenosine kinase inhibitors
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
JPH05503517A (ja)	1989-12-18	1993-06-10	バージニア・コモンウェルス・ユニバーシティ	シグマレセプターリガンド及びその用途
JPH04211063A (ja)	1990-03-05	1992-08-03	Takeda Chem Ind Ltd	縮合三環性複素環化合物、その製造法、用途及び中間体
GB9009542D0 (en)	1990-04-27	1990-06-20	Beecham Group Plc	Novel compounds
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
GB9113137D0 (en)	1990-07-13	1991-08-07	Ici Plc	Thioxo heterocycles
US5563257A (en)	1990-08-20	1996-10-08	Boehringer Mannheim Gmbh	Phospholipid derivatives of nucleosides
DE4026265A1 (de)	1990-08-20	1992-02-27	Boehringer Mannheim Gmbh	Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5190521A (en)	1990-08-22	1993-03-02	Tecnol Medical Products, Inc.	Apparatus and method for raising a skin wheal and anesthetizing skin
DK0550631T3 (da)	1990-09-25	1997-01-20	Rhone Poulenc Rorer Int	Forbindelser med blodtrykssænkende virkning og virkning mod iskæmi
US5561134A (en)	1990-09-25	1996-10-01	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5652366A (en)	1990-09-25	1997-07-29	Rhone-Poulenc Rorer Pharmaceuticals Inc.	DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
US5527288A (en)	1990-12-13	1996-06-18	Elan Medical Technologies Limited	Intradermal drug delivery device and method for intradermal delivery of drugs
GB9103839D0 (en)	1991-02-23	1991-04-10	Smithkline Beecham Plc	Pharmaceuticals
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en)	1991-05-10	2002-04-09	Aventis Pharmacetical Products, Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US6645969B1 (en)	1991-05-10	2003-11-11	Aventis Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A (en)	1991-05-10	1998-02-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
AU658646B2 (en)	1991-05-10	1995-04-27	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9118204D0 (en)	1991-08-23	1991-10-09	Weston Terence E	Needle-less injector
SE9102652D0 (sv)	1991-09-13	1991-09-13	Kabi Pharmacia Ab	Injection needle arrangement
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5916891A (en)	1992-01-13	1999-06-29	Smithkline Beecham Corporation	Pyrimidinyl imidazoles
IL104369A0 (en)	1992-01-13	1993-05-13	Smithkline Beecham Corp	Novel compounds and compositions
DE4204031A1 (de)	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
DE4204032A1 (de)	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
WO1993016082A1 (en)	1992-02-13	1993-08-19	The Upjohn Company	4-oxo- and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents
US5328483A (en)	1992-02-27	1994-07-12	Jacoby Richard M	Intradermal injection device with medication and needle guard
WO1993018035A1 (en)	1992-03-04	1993-09-16	Abbott Laboratories	Angiotensin ii receptor antagonists
JP2737518B2 (ja)	1992-03-16	1998-04-08	富士通株式会社	赤外線検知器の冷却構造
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
JPH07508711A (ja)	1992-04-07	1995-09-28	ザリージェンツオブザユニバーシティオブミシガン	Ｃｄ２８経路免疫調節
GB9208135D0 (en)	1992-04-13	1992-05-27	Ludwig Inst Cancer Res	Polypeptides having kinase activity,their preparation and use
DE69333955D1 (de)	1992-04-24	2006-02-02	Stanford Res Inst Int	Targeting homologer sequenzen in eukaryotenzellen
JP3261617B2 (ja)	1992-06-19	2002-03-04	ハネウエル・インコーポレーテッド	赤外線カメラ
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US6057305A (en)	1992-08-05	2000-05-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Antiretroviral enantiomeric nucleotide analogs
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
US5334144A (en)	1992-10-30	1994-08-02	Becton, Dickinson And Company	Single use disposable needleless injector
TW333456B (en)	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
TW370529B (en)	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
IL108523A0 (en)	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH08506343A (ja)	1993-02-03	1996-07-09	ジェンシア・インコーポレイテッド	リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質
GB9308957D0 (en)	1993-04-30	1993-06-16	Cancer Res Campaign Tech	Novel produgs
ES2240962T3 (es)	1993-06-04	2005-10-16	The United States Of America As Represented By The Secretary Of The Navy	Metodo para estimular selectivamente la proliferacion de celulas t.
US6087324A (en)	1993-06-24	2000-07-11	Takeda Chemical Industries, Ltd.	Sustained-release preparation
US5504103A (en)	1993-08-25	1996-04-02	Eli Lilly And Company	Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5525503A (en)	1993-09-28	1996-06-11	Dana-Farber Cancer Institute, Inc.	Signal transduction via CD28
WO1995012588A1 (en)	1993-11-05	1995-05-11	Biochem Pharma Inc.	Antineoplastic heteronaphthoquinones
US5656643A (en)	1993-11-08	1997-08-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5679683A (en)	1994-01-25	1997-10-21	Warner-Lambert Company	Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
WO1995024176A1 (en)	1994-03-07	1995-09-14	Bioject, Inc.	Ampule filling device
US5466220A (en)	1994-03-08	1995-11-14	Bioject, Inc.	Drug vial mixing and transfer device
US6632789B1 (en)	1994-04-29	2003-10-14	The United States Of America As Represented By The Secretary Of The Navy	Methods for modulating T cell responses by manipulating intracellular signal transduction
DE4418690A1 (de)	1994-05-28	1996-01-11	Boehringer Mannheim Gmbh	Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6323201B1 (en)	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
ATE195123T1 (de)	1995-04-03	2000-08-15	Novartis Erfind Verwalt Gmbh	Pyrazolderivate und verfahren zu deren herstellung
US6312894B1 (en)	1995-04-03	2001-11-06	Epoch Pharmaceuticals, Inc.	Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders
MX9708026A (es)	1995-04-20	1997-11-29	Pfizer	Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos.
US5977061A (en)	1995-04-21	1999-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	N6 - substituted nucleotide analagues and their use
JPH08295667A (ja)	1995-04-27	1996-11-12	Takeda Chem Ind Ltd	複素環化合物、その製造法および剤
US5593997A (en)	1995-05-23	1997-01-14	Pfizer Inc.	4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
WO1996037777A1 (en)	1995-05-23	1996-11-28	Nelson Randall W	Mass spectrometric immunoassay
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
WO1996040256A1 (en)	1995-06-07	1996-12-19	G.D. Searle & Co.	Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
ATE209047T1 (de)	1995-06-07	2001-12-15	Searle & Co	Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
JPH11509838A (ja)	1995-06-07	1999-08-31	ジー．ディー．サールアンドカンパニー	充血性心不全症を処置するためのスピロノラクトン化合物とアンギオテンシンｉｉ拮抗物質との組合わせ治療
US5665721A (en)	1995-06-07	1997-09-09	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds
AU6242096A (en)	1995-06-27	1997-01-30	Takeda Chemical Industries Ltd.	Method of producing sustained-release preparation
TW448055B (en)	1995-09-04	2001-08-01	Takeda Chemical Industries Ltd	Method of production of sustained-release preparation
JP2909418B2 (ja)	1995-09-18	1999-06-23	株式会社資生堂	薬物の遅延放出型マイクロスフイア
US5763885A (en)	1995-12-19	1998-06-09	Loral Infrared & Imaging Systems, Inc.	Method and apparatus for thermal gradient stabilization of microbolometer focal plane arrays
JPH09143163A (ja)	1995-11-29	1997-06-03	Fuji Photo Film Co Ltd	含窒素ヘテロ芳香族アミド類の製造方法
ES2183905T3 (es)	1995-12-20	2003-04-01	Hoffmann La Roche	Inhibidores de metaloproteasa de matriz.
US5893397A (en)	1996-01-12	1999-04-13	Bioject Inc.	Medication vial/syringe liquid-transfer apparatus
US5980945A (en)	1996-01-16	1999-11-09	Societe De Conseils De Recherches Et D'applications Scientifique S.A.	Sustained release drug formulations
US5747235A (en)	1996-01-26	1998-05-05	Eastman Kodak Company	Silver halide light sensitive emulsion layer having enhanced photographic sensitivity
DE19603576A1 (de)	1996-02-01	1997-08-07	Bayer Ag	Acylierte 4-Amino und 4-Hydrazinopyrimidine
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB2310952B (en)	1996-03-05	1998-08-19	Mitsubishi Electric Corp	Infrared detector
GB9607549D0 (en)	1996-04-11	1996-06-12	Weston Medical Ltd	Spring-powered dispensing device
DE69716810T2 (de)	1996-05-15	2003-02-27	Pfizer Inc., New York	2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
GB9611460D0 (en)	1996-06-01	1996-08-07	Ludwig Inst Cancer Res	Novel lipid kinase
CA2258822A1 (en)	1996-06-20	1997-12-24	Sean Kerwin	Compounds and methods for providing pharmacologically active preparations and uses thereof
US6264970B1 (en)	1996-06-26	2001-07-24	Takeda Chemical Industries, Ltd.	Sustained-release preparation
JP3195756B2 (ja)	1996-07-04	2001-08-06	公子吉水	潤滑補助体
EP0818442A3 (en)	1996-07-12	1998-12-30	Pfizer Inc.	Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
NZ333303A (en)	1996-07-18	2000-06-23	Lawrence Alan Reiter	Phosphinate based inhibitors of matrix metalloproteases
KR20000068248A (ko)	1996-08-23	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	아릴설포닐아미노 하이드록삼산 유도체
US6419961B1 (en)	1996-08-29	2002-07-16	Takeda Chemical Industries, Ltd.	Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en)	1996-10-09	1998-04-09	Sumitomo Pharmaceuticals Co., Ltd.	Sustained release formulation
US6342514B1 (en)	1996-10-23	2002-01-29	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US6251901B1 (en)	1996-10-23	2001-06-26	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US6153631A (en)	1996-10-23	2000-11-28	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5994358A (en)	1996-10-23	1999-11-30	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5965573A (en)	1996-10-23	1999-10-12	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5922753A (en)	1996-10-23	1999-07-13	Zymogenetics, Inc.	Methods for treating bone deficit conditions with benzothiazole
US5948776A (en)	1996-10-23	1999-09-07	Zymogenetic, Inc.	Compositions and methods for treating bone deficit conditions
US5990169A (en)	1996-10-23	1999-11-23	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5919808A (en)	1996-10-23	1999-07-06	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
PT839525E (pt)	1996-10-31	2004-10-29	Takeda Chemical Industries Ltd	Preparacao de libertacao prolongada
US5858753A (en)	1996-11-25	1999-01-12	Icos Corporation	Lipid kinase
AU7624798A (en)	1996-12-06	1998-06-29	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1 beta converting enzyme
AU7871298A (en)	1996-12-20	1998-07-17	Takeda Chemical Industries Ltd.	Method of producing a sustained-release preparation
US6093737A (en)	1996-12-30	2000-07-25	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
BR9714266A (pt)	1997-01-06	2000-04-18	Pfizer	Derivados de sulfona cìclicos.
JPH10206995A (ja)	1997-01-21	1998-08-07	Konica Corp	ハロゲン化銀写真感光材料
US5891474A (en)	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
DK0977733T3 (da)	1997-02-03	2003-11-24	Pfizer Prod Inc	Arylsulfonylaminohydroxamsyrederivater
WO1998034915A1 (en)	1997-02-07	1998-08-13	Pfizer Inc.	N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
AU755062B2 (en)	1997-02-07	2002-12-05	Princeton University	Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
WO1998034918A1 (en)	1997-02-11	1998-08-13	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
SK125999A3 (en)	1997-03-19	2000-05-16	Knoll Ag	Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
US5993412A (en)	1997-05-19	1999-11-30	Bioject, Inc.	Injection apparatus
WO1998052611A1 (en)	1997-05-23	1998-11-26	Nippon Shinyaku Co., Ltd.	Medicinal composition for prevention or treatment of hepatopathy
US6207679B1 (en)	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
NZ502309A (en)	1997-08-08	2002-02-01	Pfizer Prod Inc	Aryloxyarylsulfonylamino hydroxamic acid derivatives and pharmaceutical use
DE69839887D1 (de)	1997-10-02	2008-09-25	Eisai R&D Man Co Ltd	Kondensierte pyridinderivate
US6649631B1 (en)	1997-10-23	2003-11-18	The Board Of Regents Of The University Of Texas System	Compositions and methods for treating bone deficit conditions
CA2309350C (en)	1997-11-12	2007-04-03	Mitsubishi Chemical Corporation	Purine derivatives and medicaments comprising the same as active ingredient
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
IT1298087B1 (it)	1998-01-08	1999-12-20	Fiderm S R L	Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6191170B1 (en)	1998-01-13	2001-02-20	Tularik Inc.	Benzenesulfonamides and benzamides as therapeutic agents
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
JP2002505330A (ja)	1998-03-04	2002-02-19	ブリストル−マイヤーズスクイブカンパニー	ヘテロシクロ−置換イミダゾピラジン・たんぱくチロシンキナーゼ抑制剤
US6613358B2 (en)	1998-03-18	2003-09-02	Theodore W. Randolph	Sustained-release composition including amorphous polymer
JP4462654B2 (ja)	1998-03-26	2010-05-12	ソニー株式会社	映像素材選択装置及び映像素材選択方法
US6127121A (en)	1998-04-03	2000-10-03	Epoch Pharmaceuticals, Inc.	Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
US7715989B2 (en)	1998-04-03	2010-05-11	Elitech Holding B.V.	Systems and methods for predicting oligonucleotide melting temperature (TmS)
US6432970B2 (en)	1998-04-09	2002-08-13	Johns Hopkins University School Of Medicine	Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
KR19990085365A (ko)	1998-05-16	1999-12-06	허영섭	지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
JP2000072773A (ja)	1998-08-28	2000-03-07	Zeria Pharmaceut Co Ltd	プリン誘導体
AU752474B2 (en)	1998-09-18	2002-09-19	Abbott Gmbh & Co. Kg	4-aminopyrrolopyrimidines as kinase inhibitors
US6362216B1 (en)	1998-10-27	2002-03-26	Array Biopharma Inc.	Compounds which inhibit tryptase activity
ATE260255T1 (de)	1998-11-05	2004-03-15	Pfizer Prod Inc	5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
JP4876239B2 (ja)	1999-01-11	2012-02-15	プリンストンユニバーシティー	標的確認のための高親和性阻害剤およびその使用
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2000050425A1 (en)	1999-02-22	2000-08-31	Boehringer Ingelheim Pharmaceuticals, Inc.	Polycyclo heterocyclic derivatives as antiinflammatory agents
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
HRP20010665A2 (en)	1999-03-12	2003-06-30	Boehringer Ingelheim Pharma	Compounds useful as anti-inflammatory agents
EP1040831A3 (en)	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
SE515856C2 (sv)	1999-05-19	2001-10-22	Ericsson Telefon Ab L M	Bärare för elektronikkomponenter
AU5179000A (en)	1999-06-03	2000-12-28	Basf Aktiengesellschaft	Benzothiazinone and benzoxazinone compounds
US6387894B1 (en)	1999-06-11	2002-05-14	Pfizer Inc.	Use of CRF antagonists and renin-angiotensin system inhibitors
TWI262914B (en)	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1081137A1 (en)	1999-08-12	2001-03-07	Pfizer Products Inc.	Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9919588D0 (en)	1999-08-18	1999-10-20	Hoechst Schering Agrevo Gmbh	Fungicidal compounds
JP4831906B2 (ja)	1999-08-27	2011-12-07	ケモセントリックス，インコーポレイテッド	Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
US20070021493A1 (en)	1999-09-16	2007-01-25	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1216234B1 (en)	1999-09-16	2004-12-29	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2003509428A (ja)	1999-09-17	2003-03-11	アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー	治療薬としてのピラゾロピリミジン
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
WO2001021160A2 (en)	1999-09-23	2001-03-29	Axxima Pharmaceuticals Aktiengesellschaft	Carboxymide and aniline derivatives as selective inhibitors of pathogens
DE60014130T2 (de)	1999-10-06	2006-03-09	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield	Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
US6506769B2 (en)	1999-10-06	2003-01-14	Boehringer Ingelheim Pharmaceuticals, Inc.	Heterocyclic compounds useful as inhibitors of tyrosine kinases
WO2001027105A1 (en)	1999-10-12	2001-04-19	Takeda Chemical Industries, Ltd.	Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
CA2386190C (en)	1999-10-13	2009-04-14	Johns Hopkins University School Of Medicine	Regulators of the hedgehog pathway, compositions and uses related thereto
CA2286451A1 (en)	1999-10-14	2001-04-14	Grant A. Mitchell	Hormone-sensitive lipase mediated male infertility
WO2001026644A2 (en)	1999-10-14	2001-04-19	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6472153B1 (en)	1999-10-26	2002-10-29	Epoch Biosciences, Inc.	Hybridization-triggered fluorescent detection of nucleic acids
EP1095933A1 (en)	1999-10-30	2001-05-02	Aventis Pharma Deutschland GmbH	Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
US6660845B1 (en)	1999-11-23	2003-12-09	Epoch Biosciences, Inc.	Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
IL133809A0 (en)	1999-12-30	2001-04-30	Yeda Res & Dev	Steroidal alkaloids and pharmaceutical compositions comprising them
GB0002032D0 (en)	2000-01-28	2000-03-22	Zeneca Ltd	Chemical compounds
US7217722B2 (en)	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
FR2804958B1 (fr)	2000-02-15	2005-07-08	Hoechst Marion Roussel Inc	Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
US6613798B1 (en)	2000-03-30	2003-09-02	Curis, Inc.	Small organic molecule regulators of cell proliferation
DE60113823T3 (de)	2000-03-30	2010-07-01	Curis, Inc., Cambridge	Kleine organische moleküle als regulatoren der zellproliferation
US7115653B2 (en)	2000-03-30	2006-10-03	Curis, Inc.	Small organic molecule regulators of cell proliferation
US20020127625A1 (en)	2000-03-31	2002-09-12	Forskarpatent Is Syd Ab	Methods of diagnosing immune related diseases
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
PT1278748E (pt)	2000-04-25	2011-03-31	Icos Corp	Inibidores de delta 3-cinase humana de fosfatidilinositol
EP1289472A4 (en)	2000-05-30	2004-09-08	Advanced Res & Tech Inst	COMPOSITIONS AND METHODS FOR IDENTIFYING SUBSTANCES THAT MODULE THE PTEN FUNCTION AND THE PI-3 KINASE WAYS
US6667398B2 (en)	2000-06-22	2003-12-23	Pfizer Inc	Process for the preparation of pyrazolopyrimidinones
EP1294713A2 (en)	2000-06-27	2003-03-26	Genelabs Technologies, Inc.	Compounds possessing antibacterial, antifungal or antitumor activity
US6534691B2 (en)	2000-07-18	2003-03-18	E. I. Du Pont De Nemours And Company	Manufacturing process for α-olefins
WO2002028853A1 (en)	2000-10-02	2002-04-11	Tanabe Seiyaku Co., Ltd.	Benzylamine compound, process for producing the same, and intermediate therefor
US6811979B2 (en)	2000-10-11	2004-11-02	Applera Corporation	Fluorescent nucleobase conjugates having anionic linkers
AU2002213467A1 (en)	2000-10-11	2002-04-22	Chemocentryx, Inc.	Modulation of ccr4 function
FR2815346B1 (fr)	2000-10-13	2004-02-20	Servier Lab	Nouveaux composes aminotriazolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002131859A (ja)	2000-10-19	2002-05-09	Konica Corp	撮影用赤外感光性ハロゲン化銀写真感光材料及び赤外感光性ハロゲン化銀乳剤
US6890747B2 (en)	2000-10-23	2005-05-10	Warner-Lambert Company	Phosphoinositide 3-kinases
EP1343505A1 (en)	2000-12-11	2003-09-17	Tularik Inc.	Cxcr3 antagonists
CN100471838C (zh)	2000-12-28	2009-03-25	第一制药株式会社	Vla-4抑制剂
EP1353674A1 (en)	2000-12-29	2003-10-22	Alteon, Inc.	Method for treating glaucoma ivb
EP1359911A2 (en)	2000-12-29	2003-11-12	Alteon, Inc.	Method for treating fibrotic diseases or other indications ivc
EP2360166A1 (en)	2001-01-22	2011-08-24	Merck Sharp & Dohme Corp.	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7105499B2 (en)	2001-01-22	2006-09-12	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0102239D0 (en)	2001-01-29	2001-03-14	Cancer Res Ventures Ltd	Methods of chemical synthisis
PA8539401A1 (es)	2001-02-14	2002-10-28	Warner Lambert Co	Quinazolinas como inhibidores de mmp-13
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
MXPA03008560A (es)	2001-03-22	2004-06-30	Abbot Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
US7250569B2 (en)	2001-04-26	2007-07-31	New York University School Of Medicine	Method for dissolving nanostructural materials
ES2282410T3 (es)	2001-05-08	2007-10-16	Kudos Pharmaceuticals Limited	Derivados de isoquinolinona como inhibidores de parp.
NZ518726A (en)	2001-05-09	2004-06-25	Warner Lambert Co	Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US7144903B2 (en)	2001-05-23	2006-12-05	Amgen Inc.	CCR4 antagonists
US6825228B2 (en)	2001-06-13	2004-11-30	Genesoft Pharmaceuticals, Inc.	Benzothiophene compounds having antiinfective activity
WO2002101007A2 (en)	2001-06-13	2002-12-19	Genesoft Pharmaceuticals, Inc	Antipathogenic benzamide compounds
US6777425B2 (en)	2001-06-13	2004-08-17	Genesoft Pharmaceuticals, Inc.	Isoquinoline compounds having antiinfective activity
WO2003000187A2 (en)	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
DE10134721A1 (de)	2001-07-17	2003-02-06	Bayer Ag	Tetrahydrochinoxaline
EA007339B1 (ru)	2001-07-27	2006-08-25	Кьюэрис, Инк.	Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
EP1414443B1 (en)	2001-08-01	2006-11-15	Merck & Co., Inc.	BENZIMIDAZO 4,5-f\|ISOQUINOLINONE DERIVATIVES
WO2003020880A2 (en)	2001-08-03	2003-03-13	Abbott Laboratories	Method of identifying inhibitors of lck
WO2003016275A1 (fr)	2001-08-10	2003-02-27	Shionogi & Co., Ltd.	Agent antiviral
JP2003073357A (ja)	2001-09-03	2003-03-12	Mitsubishi Pharma Corp	アミド化合物を含有するＲｈｏキナーゼ阻害剤
US20030199516A1 (en)	2001-09-13	2003-10-23	Genesoft, Inc.	Methods of treating infection by drug resistant bacteria
US7101884B2 (en)	2001-09-14	2006-09-05	Merck & Co., Inc.	Tyrosine kinase inhibitors
AUPR769501A0 (en)	2001-09-14	2001-10-11	Biomolecular Research Institute Limited	Cytokine receptor 1
US8124625B2 (en)	2001-09-14	2012-02-28	Shionogi & Co., Ltd.	Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7269663B2 (en)	2001-09-28	2007-09-11	Intel Corporation	Tagging packets with a lookup key to facilitate usage of a unified packet forwarding cache
TWI330183B (es)	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
KR20040048920A (ko)	2001-11-01	2004-06-10	얀센 파마슈티카 엔.브이.	글리코겐 신타아제 키나제 3-베타 저해제(ｇｓｋ저해제)로서의 헤테로아릴 아민
BR0214019A (pt)	2001-11-09	2004-10-13	Boehringer Ingelheim Phamaceut	Benzimidazóis úteis como inibidores de proteìna quinase
DE10159269A1 (de)	2001-12-03	2003-06-18	Bayer Ag	Arylierung von Olefinen
DE10159270A1 (de)	2001-12-03	2003-06-12	Bayer Ag	Verfahren zur Arylierung von Olefinen
WO2003048081A2 (en)	2001-12-04	2003-06-12	Bristol-Myers Squibb Company	Glycinamides as factor xa inhibitors
JP4085237B2 (ja)	2001-12-21	2008-05-14	日本電気株式会社	携帯電話の利用契約システムと通信方法
EP1465869B1 (en)	2001-12-21	2013-05-15	Exelixis Patent Company LLC	Modulators of lxr
US7064218B2 (en)	2001-12-26	2006-06-20	Genelabs Technologies, Inc.	Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity
US7414036B2 (en)	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
US20040043959A1 (en)	2002-03-04	2004-03-04	Bloom Laura A.	Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2003225933A1 (en)	2002-03-22	2003-10-13	Cellular Genomics, Inc.	AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
CA2480468C (en)	2002-03-26	2012-03-13	Biofrontera Discovery Gmbh	Fredericamycin derivatives
US7166293B2 (en)	2002-03-29	2007-01-23	Carlsbad Technology, Inc.	Angiogenesis inhibitors
DE10217046A1 (de)	2002-04-17	2003-11-06	Bioleads Gmbh	Fredericamycin-Derivate
EP1496905B1 (en)	2002-04-22	2008-08-13	Johns Hopkins University School of Medicine	Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2003090751A1 (en)	2002-04-26	2003-11-06	Pfizer Products Inc.	Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
US6794562B2 (en)	2002-05-01	2004-09-21	Stine Seed Farm, Inc.	Soybean cultivar 0332143
AU2003299517A1 (en)	2002-05-23	2004-05-25	Merck & Co., Inc.	Mitotic kinesin inhibitors
AU2003236527A1 (en)	2002-06-14	2003-12-31	Cytokinetics, Inc.	Compounds, compositions, and methods
US7265111B2 (en)	2002-06-27	2007-09-04	Sanofi-Aventis Deutschland Gmbh	Adenosine analogues and their use as pharmaceutical agents
KR101124245B1 (ko)	2002-06-27	2012-07-02	노보 노르디스크 에이/에스	치료제로서 아릴 카르보닐 유도체
MXPA05000130A (es)	2002-06-27	2005-02-17	Novo Nordisk As	Derivados de aril-carbonilo como agentes terapeuticos.
DE10230917A1 (de)	2002-07-09	2004-02-05	Bioleads Gmbh	Fredericamycin-Derivate
AU2003249244A1 (en)	2002-07-15	2004-02-02	Combinatorx, Incorporated	Methods for the treatment of neoplasms
EP1394159A1 (fr)	2002-08-13	2004-03-03	Warner-Lambert Company LLC	Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CA2494048A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
NZ538420A (en)	2002-08-16	2007-06-29	Kinacia Pty Ltd	Inhibition of phosphoinositide 3-kinase beta
JP2005536553A (ja)	2002-08-21	2005-12-02	サイトキネティクス・インコーポレーテッド	化合物、組成物および方法
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004020599A2 (en)	2002-08-29	2004-03-11	Curis, Inc.	Hedgehog antagonists, methods and uses related thereto
GB0220319D0 (en)	2002-09-02	2002-10-09	Cancer Res Campaign Tech	Enzyme activated self-immolative nitrogen mustard drugs
AU2003266668A1 (en)	2002-09-30	2004-04-23	Banyu Pharmaceutical Co., Ltd.	2-aminobenzimidazole derivative
KR20110050745A (ko)	2002-10-03	2011-05-16	탈자진 인코포레이티드	혈관항상성 유지제 및 그의 사용 방법
US20050282814A1 (en)	2002-10-03	2005-12-22	Targegen, Inc.	Vasculostatic agents and methods of use thereof
US20040146941A1 (en)	2002-11-04	2004-07-29	Biliang Zhang	Chemical encoding technology for combinatorial synthesis
JP2004161716A (ja)	2002-11-15	2004-06-10	Takeda Chem Ind Ltd	Ｊｎｋ阻害剤
AU2003286251A1 (en)	2002-11-21	2004-06-15	Vicore Pharma Ab	New bicyclic angiotensin ii agonists
US7265131B2 (en)	2002-12-20	2007-09-04	Exelixis, Inc.	Isoquinolinone derivatives and their use as therapeutic agents
US7247736B2 (en)	2002-12-23	2007-07-24	4Sc Ag	Method of identifying inhibitors of DHODH
US7365094B2 (en)	2002-12-23	2008-04-29	4Sc Ag	Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056746A1 (en)	2002-12-23	2004-07-08	4Sc Ag	Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
FR2850022B1 (fr)	2003-01-22	2006-09-08	Centre Nat Rech Scient	Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2004075917A1 (ja)	2003-02-28	2004-09-10	Toudai Tlo, Ltd.	器官または組織の線維化抑制剤
US20060135790A1 (en)	2003-03-06	2006-06-22	Hyett David J	Process for the preparation of an alpha-amino carbonyl compound
AR043633A1 (es)	2003-03-20	2005-08-03	Schering Corp	Ligandos de receptores de canabinoides
US20040242568A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
GB0306907D0 (en)	2003-03-26	2003-04-30	Angiogene Pharm Ltd	Boireductively-activated prodrugs
WO2004087679A1 (en)	2003-04-01	2004-10-14	Aponetics Ag	2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
US7217794B2 (en)	2003-04-02	2007-05-15	Daiamed, Inc.	Compounds and methods for treatment of thrombosis
WO2004089877A1 (en)	2003-04-14	2004-10-21	Astrazeneca Ab	New hydroxynaphthyl amides
US7317027B2 (en)	2003-05-19	2008-01-08	Sanofi-Aventis Deutschland Gmbh	Azaindole-derivatives as factor Xa inhibitors
EP1479675A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Indazole-derivatives as factor Xa inhibitors
US7223780B2 (en)	2003-05-19	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1646615B1 (en)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
US7429596B2 (en)	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2572324A1 (en)	2003-07-02	2005-01-13	Warner-Lambert Company Llc	Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005013800A2 (en)	2003-07-15	2005-02-17	The Johns Hopkins University	Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
GB0317951D0 (en)	2003-07-31	2003-09-03	Trigen Ltd	Compounds
WO2005014532A1 (en)	2003-08-08	2005-02-17	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
WO2005016349A1 (en)	2003-08-14	2005-02-24	Icos Corporation	Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en)	2003-08-14	2005-02-24	Icos Corporation	Method of inhibiting immune responses stimulated by an endogenous factor
US20050124637A1 (en)	2003-08-15	2005-06-09	Irm Llc	Compounds and compositions as inhibitors of receptor tyrosine kinase activity
US7390820B2 (en)	2003-08-25	2008-06-24	Amgen Inc.	Substituted quinolinone derivatives and methods of use
WO2005044181A2 (en)	2003-09-09	2005-05-19	Temple University-Of The Commonwealth System Of Higher Education	Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
US8067608B2 (en)	2003-09-29	2011-11-29	The Johns Hopkins University	Hedgehog pathway antagonists
WO2005032343A2 (en)	2003-10-01	2005-04-14	The Johns Hopkins University	Hedgehog signaling in prostate regeneration neoplasia and metastasis
WO2005042700A2 (en)	2003-10-20	2005-05-12	The Johns Hopkins University	Use of hedgehog pathway inhibitors in small-cell lung cancer
TWI344364B (en)	2003-11-10	2011-07-01	Synta Pharmaceuticals Corp	Fused heterocyclic compounds
EP1687309A1 (en)	2003-11-17	2006-08-09	Pfizer Products Inc.	Pyrrolopyrimidine compounds useful in treatment of cancer
WO2005054202A1 (en) *	2003-11-25	2005-06-16	Eli Lilly And Company	7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
WO2005061460A1 (en)	2003-12-08	2005-07-07	Cytokinetics, Inc.	Compounds, compositions, and methods
AU2004308974A1 (en)	2003-12-22	2005-07-14	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates
PL1699800T3 (pl)	2003-12-23	2010-07-30	Novartis Ag	Bicykliczne heterocykliczne inhibitory kinazy p-38
US20050239809A1 (en)	2004-01-08	2005-10-27	Watts Stephanie W	Methods for treating and preventing hypertension and hypertension-related disorders
WO2005070457A1 (en)	2004-01-23	2005-08-04	Seattle Genetics, Inc.	Melphalan prodrugs
WO2005074603A2 (en)	2004-02-03	2005-08-18	Abbott Laboratories	Aminobenzoxazoles as therapeutic agents
EP1723467A2 (en)	2004-02-03	2006-11-22	Rochester Institute of Technology	Method of photolithography using a fluid and a system thereof
KR20070026385A (ko)	2004-02-13	2007-03-08	반유 세이야꾸 가부시끼가이샤	축합환 4-옥소피리미딘 유도체
US20050187418A1 (en)	2004-02-19	2005-08-25	Small Brooke L.	Olefin oligomerization
JP2007523202A (ja)	2004-02-24	2007-08-16	ビオアクソン・テラプティーク・インコーポレーテッド	４置換ピペリジン誘導体
EP1568698A1 (en)	2004-02-27	2005-08-31	Aventis Pharma Deutschland GmbH	Pyrrole-derivatives as factor Xa inhibitors
CA2557575A1 (en)	2004-02-27	2005-09-15	F. Hoffmann-La Roche Ag	Fused derivatives of pyrazole
EP1571154A1 (en)	2004-03-03	2005-09-07	Aventis Pharma Deutschland GmbH	Beta-aminoacid-derivatives as factor Xa inhibitors
AU2005230818B2 (en)	2004-04-02	2010-11-25	Osi Pharmaceuticals, Inc.	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8273743B2 (en)	2004-04-30	2012-09-25	Curis, Inc.	Quinoxaline inhibitors of the hedgehog signalling
US9212149B2 (en)	2004-04-30	2015-12-15	Takeda Pharmaceutical Company Limited	Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
DE102004022897A1 (de)	2004-05-10	2005-12-08	Bayer Cropscience Ag	Azinyl-imidazoazine
JP2007537291A (ja)	2004-05-13	2007-12-20	イコス・コーポレイション	ヒトホスファチジルイノシトール３−キナーゼデルタの阻害剤としてのキナゾリノン
WO2005112935A1 (en)	2004-05-13	2005-12-01	Vanderbilt University	Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
JP2008500338A (ja)	2004-05-25	2008-01-10	イコス・コーポレイション	造血細胞の異常増殖を治療及び／又は予防する方法
WO2005120511A1 (en)	2004-06-04	2005-12-22	Icos Corporation	Methods for treating mast cell disorders
GB0413605D0 (en)	2004-06-17	2004-07-21	Addex Pharmaceuticals Sa	Novel compounds
US7553838B2 (en)	2004-07-01	2009-06-30	Merck & Co. Inc.	Mitotic kinesin inhibitors
US20060019967A1 (en)	2004-07-21	2006-01-26	Su-Ying Wu	SARS CoV main protease inhibitors
WO2006015279A1 (en)	2004-07-28	2006-02-09	Neurogen Corporation	Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
US7230004B2 (en)	2004-08-27	2007-06-12	Infinity Discovery, Inc.	Cyclopamine analogues and methods of use thereof
UA96565C2 (ru)	2004-09-02	2011-11-25	Дженентек, Инк.	Пиридильные ингибиторы хеджхоговской передачи сигнала
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
WO2006038865A1 (en)	2004-10-01	2006-04-13	Betagenon Ab	Nucleotide derivatives for the treatment of type 2 diabetes and other disorders
CN101083996A (zh)	2004-10-28	2007-12-05	Irm责任有限公司	作为hedgehog途径调节剂的化合物和组合物
US8212012B2 (en)	2004-11-03	2012-07-03	University Of Kansas	Novobiocin analogues having modified sugar moieties
US8212011B2 (en)	2004-11-03	2012-07-03	University Of Kansas	Novobiocin analogues
US7622451B2 (en)	2004-11-03	2009-11-24	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
AU2005301957B2 (en)	2004-11-03	2012-02-23	Department Of Health And Human Services	Novobiocin analogues as anticancer agents
GB0425035D0 (en)	2004-11-12	2004-12-15	Novartis Ag	Organic compounds
WO2006068760A2 (en)	2004-11-19	2006-06-29	The Regents Of The University Of California	Anti-inflammatory pyrazolopyrimidines
WO2006065479A2 (en)	2004-11-23	2006-06-22	Ptc Therapeutics, Inc.	Substituted phenols as active agents inhibiting vegf production
KR20070094754A (ko)	2004-12-01	2007-09-21	데브젠 엔브이	이온 채널, 특히 Ｋｖ 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체
US20060156485A1 (en)	2005-01-14	2006-07-20	The Procter & Gamble Company	Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0501999D0 (en)	2005-02-01	2005-03-09	Sentinel Oncology Ltd	Pharmaceutical compounds
WO2006089106A2 (en)	2005-02-17	2006-08-24	Icos Corporation	Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
US7579348B2 (en)	2005-02-25	2009-08-25	Pgxhealth, Llc	Derivatives of 8-substituted xanthines
US20090124654A1 (en)	2005-03-01	2009-05-14	Mjalli Adnan M M	Aryl and Heteroaryl Compounds, Compositions, Methods of Use
US7872050B2 (en)	2005-03-14	2011-01-18	Yaupon Therapeutics Inc.	Stabilized compositions of volatile alkylating agents and methods of using thereof
RU2007140733A (ru)	2005-04-06	2009-05-20	Айрм Ллк (Bm)	Диариламинсодержащие соединения и композиции, и их применение в качестве модуляторов ядерных рецепторов стероидного гормона
KR100781704B1 (ko)	2005-04-20	2007-12-03	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
AU2006239677A1 (en)	2005-04-25	2006-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Use of compounds to enhance processivity of telomerase
CN100526315C (zh)	2005-06-16	2009-08-12	浙江医药股份有限公司新昌制药厂	N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
SG10201504801VA (en)	2005-06-22	2015-07-30	Chemocentryx Inc	Azaindazole compounds and methods of use
CA2612585A1 (en)	2005-06-27	2007-01-04	Amgen Inc.	Anti-inflammatory aryl nitrile compounds
WO2007006546A1 (en)	2005-07-11	2007-01-18	Devgen N.V.	Amide derivatives as kinase inhibitors
JP2009500437A (ja)	2005-07-11	2009-01-08	デブジェンエヌブイ	キナーゼ阻害剤としてのアミド誘導体
WO2007029121A2 (en)	2005-07-21	2007-03-15	Galderma Research & Development	Novel cyclopent-2-en-1-one derivatives which are ppar receptor modulators, and use thereof in pharmaceutical or cosmetic compositions
US20070017915A1 (en)	2005-07-22	2007-01-25	Weder Donald E	Collapsible and/or erectable substantially egg-shaped container
JP2009502845A (ja)	2005-07-29	2009-01-29	メディヴィル・アクチボラグ	Ｃ型肝炎ウイルスの大環状インヒビター
GB0516723D0 (en)	2005-08-15	2005-09-21	Novartis Ag	Organic compounds
US20070049591A1 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Inhibitors of MAPK/Erk Kinase
MX2008002385A (es)	2005-08-25	2008-03-18	Hoffmann La Roche	Inhibidores de proteinas cinasas activads por mitogenos p38 y metodos para utilizarlos.
US20080318942A1 (en)	2005-09-01	2008-12-25	Bioagency Ag	Fredericamycin Derivatives
US20100022531A1 (en)	2005-09-01	2010-01-28	Renovis, Inc.	Novel compounds as p2x7 modulators and uses thereof
US20070072897A1 (en)	2005-09-29	2007-03-29	Wyeth	Phenylaminopropanol derivatives and methods of their use
FR2892859B1 (fr)	2005-10-27	2008-06-06	Commissariat Energie Atomique	Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications
WO2007054623A2 (en)	2005-11-11	2007-05-18	Licentia Oy	Mammalian hedgehog signaling inhiabitors
JP5225857B2 (ja)	2005-11-14	2013-07-03	ジェネンテック，インコーポレイティド	ヘッジホッグシグナル伝達のビスアミド阻害剤
ES2365869T3 (es)	2005-11-17	2011-10-11	OSI Pharmaceuticals, LLC	COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
US20090088452A1 (en)	2005-11-22	2009-04-02	Coleman Paul J	Indole Orexin Receptor Antagonists
CA2630920A1 (en)	2005-11-22	2007-05-31	University Of South Florida	Inhibition of cell proliferation
US7572809B2 (en)	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
JP2009520028A (ja)	2005-12-19	2009-05-21	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	Ｉｇｆｒ抑制剤および抗癌剤の併用
EP1973917B1 (en)	2005-12-29	2015-06-10	AbbVie Inc.	Protein kinase inhibitors
NZ569608A (en)	2006-01-06	2011-09-30	Sepracor Inc	Tetralone-based monoamine reuptake inhibitors
WO2007094912A2 (en)	2006-01-13	2007-08-23	University Of Kentucky	Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
WO2007089669A2 (en)	2006-01-26	2007-08-09	Wyeth	Processes for the preparation of compounds which modulate cell proliferation
PE20071025A1 (es)	2006-01-31	2007-10-17	Mitsubishi Tanabe Pharma Corp	Compuesto amina trisustituido
MX2008011220A (es)	2006-03-07	2008-09-11	Array Biopharma Inc	Compuestos de pirazol heterobiciclicos y metodos de uso.
HRP20160990T1 (hr)	2006-03-24	2016-10-07	Biogen Hemophilia Inc.	Pc5 kao enzim obrade faktor ix propeptida
EP2007373A4 (en)	2006-03-29	2012-12-19	Foldrx Pharmaceuticals Inc	INHIBITION OF ALPHA SYNUCLEINE TOXICITY
GB2453058A (en)	2006-04-04	2009-03-25	Univ California	Kinase antagonists
CN101466708A (zh)	2006-04-13	2009-06-24	弗特克斯药品有限公司	可用作蛋白激酶抑制剂的噻吩甲酰胺
EP2010170A2 (en)	2006-04-14	2009-01-07	Novartis AG	Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
WO2007121453A2 (en)	2006-04-17	2007-10-25	The Regents Of The University Of California	2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
JP5373599B2 (ja)	2006-04-21	2013-12-18	ノバルティスアーゲー	アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607948D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
JP2009536620A (ja)	2006-04-25	2009-10-15	アステックス、セラピューティックス、リミテッド	医薬組み合わせ物
JP2009536161A (ja)	2006-04-25	2009-10-08	アステックス、セラピューティックス、リミテッド	医薬化合物
DE102006020327A1 (de)	2006-04-27	2007-12-27	Bayer Healthcare Ag	Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
UA93548C2 (uk)	2006-05-05	2011-02-25	Айерем Елелсі	Сполуки та композиції як модулятори хеджхогівського сигнального шляху
CN101448827A (zh)	2006-05-22	2009-06-03	阿斯利康(瑞典)有限公司	吲哚衍生物
GB0610242D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
DE602006018877D1 (de)	2006-05-24	2011-01-27	Guardant S R L	Alkalisiertes Lokalanästhetikum im Beutel
GB0610317D0 (en)	2006-05-24	2006-07-05	Medical Res Council	Antiparasitic compounds and compositions
WO2008011109A2 (en)	2006-07-20	2008-01-24	Amgen Inc.	Substituted pyridone compounds and methods of use
MX2009000864A (es)	2006-07-28	2009-02-03	Novartis Ag	Quinazolinas 2,4-sustituidas como inhibidores de cinasa de lipido.
WO2008020203A1 (en)	2006-08-17	2008-02-21	Astrazeneca Ab	Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
EP2061764B1 (en)	2006-08-22	2014-07-02	Technion Research & Development Foundation LTD.	Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
JP2010501593A (ja)	2006-08-24	2010-01-21	セレネックス，インコーポレイテッド	イソキノリン、キナゾリンおよびフタラジン誘導体
US7956064B2 (en)	2006-09-01	2011-06-07	Cylene Pharmaceuticals, Inc.	Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
WO2008025755A1 (de)	2006-09-01	2008-03-06	Basf Se	Verwendung von n-haltigen heterozyklen in dermokosmetika
EP1903044A1 (en)	2006-09-14	2008-03-26	Novartis AG	Adenosine Derivatives as A2A Receptor Agonists
EP2064234B1 (en)	2006-09-18	2011-11-02	Compugen Ltd.	Bioactive peptides and method of using same
JP5306818B2 (ja)	2006-10-18	2013-10-02	武田薬品工業株式会社	縮合複素環化合物
EP2431388A1 (en)	2006-10-31	2012-03-21	Government of the United States of America, Represented by the Secretary, Department of Health and Human Services	Smoothened polypeptides and methods of use
US7772180B2 (en)	2006-11-09	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US20100216820A1 (en)	2006-11-13	2010-08-26	White Stephen L	Thienopyrimidiones for treatment of inflammatory disorders and cancers
WO2008063625A2 (en)	2006-11-20	2008-05-29	Adolor Corporation	Pyridine compounds and methods of their use
MY150216A (en) *	2006-11-20	2013-12-13	Novartis Ag	Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
US8658637B2 (en)	2006-12-06	2014-02-25	Boehringer Ingelheim International Gmbh	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
EP2103619A4 (en)	2006-12-14	2011-11-23	Daiichi Sankyo Co Ltd	IMIDAZOTHIAZOLDERIVATE
JP5178738B2 (ja)	2006-12-20	2013-04-10	メルク・シャープ・アンド・ドーム・コーポレーション	新規なｊｎｋ阻害剤
CA2674525A1 (en)	2006-12-22	2008-07-03	Albert Einstein College Of Medicine Of Yeshiva University	Azetidine analogues of nucleosidase and phosphorylase inhibitors
ATE490243T1 (de) *	2006-12-27	2010-12-15	Sanofi Aventis	Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
TWI433674B (zh)	2006-12-28	2014-04-11	Infinity Discovery Inc	環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EA200900983A1 (ru)	2007-01-26	2010-02-26	Айрм Ллк	Соединения и композиции в качестве ингибиторов киназы
US20080200461A1 (en)	2007-02-20	2008-08-21	Cropsolution, Inc.	Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
WO2008109829A1 (en)	2007-03-07	2008-09-12	Infinity Pharmaceuticals, Inc.	Cyclopamine lactam analogs and methods of use thereof
RU2009137014A (ru)	2007-03-07	2011-04-20	Инфинити Дискавери, Инк. (Us)	Гетероциклические аналоги циклопамина и способы их применения
CN101686952A (zh)	2007-03-12	2010-03-31	Vm生物医药公司	新型钙离子通道调节剂
NZ598251A (en)	2007-03-14	2013-06-28	Exelixis Patent Co Llc	2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer
MX2009009873A (es)	2007-03-15	2009-09-24	Novartis Ag	Compuestos organicos y sus usos.
WO2008118454A2 (en)	2007-03-23	2008-10-02	Amgen Inc.	Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
MX2009009968A (es)	2007-03-23	2009-10-08	Amgen Inc	Compuestos heterociclicos y sus usos.
PL2139882T3 (pl)	2007-03-23	2014-05-30	Amgen Inc	3-podstawione pochodne chinoliny lub chinoksaliny i ich zastosowanie jako inhibitorów 3-kinazy fosfatydyloinozytolu (pi3k)
WO2008117050A1 (en)	2007-03-27	2008-10-02	Astrazeneca Ab	Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
WO2008156513A2 (en)	2007-03-29	2008-12-24	University Of Connecticut	Methods to protect skeletal muscle against injury
CA2683578A1 (en)	2007-04-13	2008-10-23	Sanofi-Aventis	A transition metal catalyzed synthesis of n-aminoindoles
WO2008125014A1 (fr)	2007-04-13	2008-10-23	Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A.	Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques
WO2008131354A2 (en)	2007-04-20	2008-10-30	The Curators Of The University Of Missouri	Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment
WO2008131779A1 (en) *	2007-04-26	2008-11-06	H. Lundbeck A/S	Isoquinolinone derivatives as nk3 antagonists
JP2010163361A (ja)	2007-04-27	2010-07-29	Dainippon Sumitomo Pharma Co Ltd	キノリン誘導体
US7960353B2 (en)	2007-05-10	2011-06-14	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
TW200902016A (en)	2007-05-22	2009-01-16	Taigen Biotechnology Co Ltd	Kinesin inhibitors
US9603848B2 (en)	2007-06-08	2017-03-28	Senomyx, Inc.	Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8557823B2 (en)	2007-06-18	2013-10-15	Advanced Cancer Therapeutics, Llc	Family of PFKFB3 inhibitors with anti-neoplastic activities
WO2008156783A2 (en)	2007-06-18	2008-12-24	University Of Louisville Research Foundation, Inc.	Family of pfkfb3 inhibitors with anti-neoplastic activities
MX2009013869A (es)	2007-06-21	2010-03-17	Amgen Inc	Proceso para hacer 2-amino-tiazolonas sustituidas.
ATE538120T1 (de)	2007-06-26	2012-01-15	Sanofi Sa	Regioselektive, metallkatalysierte synthese annelierter benzimidazole und azabenzimidazole
EP2170274A1 (en)	2007-07-02	2010-04-07	Technion Research and Development Foundation, Ltd.	Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
RU2345996C1 (ru)	2007-07-17	2009-02-10	Андрей Александрович Иващенко	Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
JP4846769B2 (ja)	2007-07-30	2011-12-28	田辺三菱製薬株式会社	医薬組成物
JP4834699B2 (ja)	2007-07-30	2011-12-14	田辺三菱製薬株式会社	医薬組成物
EP2190466A4 (en)	2007-08-10	2011-12-21	Burnham Inst Medical Research	Tissue-specific alkaline phosphatase (TNAP) activators and their use
MX2010001784A (es)	2007-08-13	2010-03-15	Metabasis Therapeutics Inc	Activadores novedosos de la glucocinasa.
WO2009029617A1 (en)	2007-08-27	2009-03-05	Kalypsys, Inc.	Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
WO2009044707A1 (ja)	2007-10-03	2009-04-09	Riken	ニトロトリアゾール誘導体、およびそれを用いる化合物の製造方法
KR20100089082A (ko)	2007-10-15	2010-08-11	아스트라제네카 아베	조합 059
JP2011503193A (ja)	2007-11-13	2011-01-27	アイコス、コーポレーション	ヒトホスファチジルイノシトール３−キナーゼδの阻害剤
US20090163481A1 (en)	2007-12-13	2009-06-25	Murphy Brian J	Ppar-delta ligands and methods of their use
JP5620821B2 (ja)	2007-12-13	2014-11-05	シエナビオテクソシエタペルアチオニＳｉｅｎａＢｉｏｔｅｃｈＳ．Ｐ．Ａ．	ヘッジホッグ経路拮抗薬およびその治療用途
ES2587738T3 (es)	2007-12-21	2016-10-26	Ucb Biopharma Sprl	Derivados de quinoxalina y quinolina como inhibidores de quinasa
US7960397B2 (en)	2007-12-28	2011-06-14	Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic	6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
US7894450B2 (en)	2007-12-31	2011-02-22	Nortel Network, Ltd.	Implementation of VPNs over a link state protocol controlled ethernet network
AU2009204487C1 (en)	2008-01-04	2014-10-16	Intellikine, Llc	Certain chemical entities, compositions and methods
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP2011509305A (ja)	2008-01-09	2011-03-24	ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー	Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療
WO2009088086A1 (ja)	2008-01-10	2009-07-16	Asahi Glass Company, Limited	ガラス、発光装置用の被覆材および発光装置
DE102008004644A1 (de)	2008-01-16	2009-07-23	Robert Bosch Gmbh	Monostatische Mehrstrahlradarsensorvorrichtung für ein Kraftfahrzeug
WO2009100406A2 (en)	2008-02-07	2009-08-13	Synta Pharmaceuticals Corp.	Topical formulations for the treatment of psoriasis
CA2714516A1 (en)	2008-02-07	2009-08-13	Gilead Palo Alto, Inc.	Abca-1 elevating compounds and the use thereof
WO2009103022A1 (en)	2008-02-13	2009-08-20	Itherx Pharmaceuticals, Inc.	Derivatives of substituted fused ring cycloindoles and methods of their use
TWI444384B (zh)	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009105782A1 (en)	2008-02-21	2009-08-27	Sequoia Pharmaceuticals, Inc.	Hiv protease inhibitor and cytochrome p450 inhibitor combinations
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
CA2716856C (en)	2008-03-20	2013-02-19	Amgen Inc.	Aurora kinase modulators and method of use
WO2009118765A2 (en)	2008-03-28	2009-10-01	Panacea Biotec Limited	Novel monoamine re-uptake inhibitor
CA2721851A1 (en)	2008-05-30	2009-12-03	Genentech, Inc.	Purine pi3k inhibitor compounds and methods of use
US20090312406A1 (en)	2008-06-12	2009-12-17	Hsing-Pang Hsieh	Coumarin compounds and their use for treating viral infection
CA2727674A1 (en)	2008-06-20	2010-01-21	Amgen Inc.	Process for making substituted 2-amino-thiazolones
WO2010006072A2 (en)	2008-07-08	2010-01-14	The Regents Of The University Of California	Mtor modulators and uses thereof
MX2011000216A (es)	2008-07-08	2011-03-29	Intellikine Inc	Inhibidores de cinasa y metodos para su uso.
CA2730610A1 (en)	2008-07-16	2010-01-21	Schering Corporation	Bicyclic heterocycle derivatives and their use as gpcr modulators
US8450344B2 (en)	2008-07-25	2013-05-28	Aerie Pharmaceuticals, Inc.	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
AU2009282480B2 (en)	2008-08-11	2015-05-07	Children's Medical Center Corporation	Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US20110190157A1 (en)	2008-08-15	2011-08-04	The Regents Of The University Of California	Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
CN102186479A (zh)	2008-09-10	2011-09-14	凯利普西斯公司	用于治疗疾病的组胺受体的氨基嘧啶抑制剂
US8513295B2 (en)	2008-09-23	2013-08-20	Georgetown University	Viral and fungal inhibitors
EP2346508B1 (en)	2008-09-26	2016-08-24	Intellikine, LLC	Heterocyclic kinase inhibitors
EP2177510A1 (en)	2008-10-17	2010-04-21	Universität des Saarlandes	Allosteric protein kinase modulators
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
WO2010053998A1 (en)	2008-11-05	2010-05-14	Xenon Pharmaceuticals, Inc.	Spiro-condensed indole derivatives as sodium channel inhibitors
CN104042618B (zh)	2008-11-13	2018-02-16	吉利德卡利斯托加公司	恶性血液病的治疗
US20110269779A1 (en)	2008-11-18	2011-11-03	Intellikine, Inc.	Methods and compositions for treatment of ophthalmic conditions
WO2010065923A2 (en)	2008-12-04	2010-06-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
CN103724328B (zh)	2008-12-19	2015-10-14	贝林格尔.英格海姆国际有限公司	作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
CN102361640B (zh)	2009-01-13	2016-10-19	范安德尔研究所	异噁唑吡啶酮在制备用于缓解或减轻温血哺乳动物关节炎和哮喘的症状的药物中的用途
US20110135655A1 (en)	2009-01-13	2011-06-09	PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine;	Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
US8513284B2 (en)	2009-02-13	2013-08-20	Ucb Pharma, S.A.	Fused pyridine and pyrazine derivatives as kinase inhibitors
TW201038569A (en)	2009-02-16	2010-11-01	Abbott Gmbh & Co Kg	Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US20100280067A1 (en)	2009-04-30	2010-11-04	Pakala Kumara Savithru Sarma	Inhibitors of acetyl-coa carboxylase
CA2760791C (en)	2009-05-07	2017-06-20	Intellikine, Inc.	Heterocyclic compounds and uses thereof
US20120190666A1 (en) *	2009-05-13	2012-07-26	Amgen Inc.	Heteroaryl Compounds as PIKK Inhibitors
GB0908957D0 (en)	2009-05-22	2009-07-01	Ucb Pharma Sa	Therapeutic agents
CA2763099A1 (en)	2009-05-22	2010-11-25	Exelixis, Inc.	Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
CA2763008A1 (en)	2009-05-26	2010-12-02	Exelixis, Inc.	Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
SG182247A1 (en)	2009-05-27	2012-08-30	Hoffmann La Roche	Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
BRPI1009022A2 (pt)	2009-05-27	2016-03-08	Hoffmann La Roche	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
CN101602768B (zh)	2009-07-17	2012-05-30	河南省农科院农副产品加工研究所	一种芝麻素和芝麻林素的提纯方法
US9212177B2 (en)	2009-08-05	2015-12-15	Versitech Limited	Antiviral compounds and methods of making and using thereof
CA2775942A1 (en)	2009-09-29	2011-04-07	Xcovery Holding Company Llc	Pi3k (delta) selective inhibitors
US8106146B2 (en)	2009-10-06	2012-01-31	Medtronic, Inc.	Therapeutic polymers and methods of generation
WO2011058108A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Quinoline and quinoxaline derivatives as kinase inhibitors
WO2011058109A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
US8637543B2 (en)	2009-11-12	2014-01-28	Ucb Pharma S.A.	Quinoline derivatives as kinase inhibitors
AU2010319298B2 (en)	2009-11-13	2015-11-05	Plastipak Packaging, Inc.	Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
US20120238559A1 (en)	2009-12-03	2012-09-20	Glaxo Group Limited	Novel compounds
WO2011072275A2 (en)	2009-12-11	2011-06-16	Nono, Inc.	Agents and methods for treating ischemic and other diseases
JP2013514989A (ja)	2009-12-18	2013-05-02	アムジエン・インコーポレーテツド	複素環式化合物およびその使用法
WO2011087776A1 (en)	2009-12-22	2011-07-21	Vertex Pharmaceuticals Incorporated	Isoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN102883602B (zh)	2010-02-16	2017-07-18	Uwm研究基金会有限公司	降低细菌的毒力的方法
WO2011111880A1 (ko)	2010-03-08	2011-09-15	주식회사 메디젠텍	세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
CN102206172B (zh)	2010-03-30	2015-02-25	中国医学科学院医药生物技术研究所	一组取代双芳基化合物及其制备方法和抗病毒应用
WO2011133729A2 (en)	2010-04-23	2011-10-27	Kineta, Inc.	Anti-viral compounds
MX2012012353A (es)	2010-04-23	2013-02-07	Kineta Inc	Compuestos anti-virales.
ES2834973T3 (es)	2010-05-04	2021-06-21	Alkermes Pharma Ireland Ltd	Procedimiento de síntesis de compuestos de lactama oxidada
ES2593256T3 (es)	2010-05-21	2016-12-07	Infinity Pharmaceuticals, Inc.	Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
JP5911476B2 (ja)	2010-05-26	2016-04-27	スノビオンプハルマセウトイカルスインコーポレイテッド	ヘテロアリール化合物及びその使用方法
US20120142701A1 (en)	2010-05-28	2012-06-07	The University Of Hong Kong	Compounds and methods for the treatment of proliferative diseases
NZ736048A (en)	2010-06-03	2019-09-27	Pharmacyclics Llc	The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2579878A1 (en)	2010-06-11	2013-04-17	Gilead Calistoga LLC	Methods of treating hematological disorders with quinazolinone compounds in selected patients
WO2011163610A2 (en)	2010-06-25	2011-12-29	Rutgers, The State University Of New Jersey	Antimicrobial agents
BR112012033658A2 (pt)	2010-07-05	2016-11-29	Merck Patent Gmbh	derivados bipiridílicos úteis para o tratamento de doenças induzidas por quinases
US8906943B2 (en)	2010-08-05	2014-12-09	John R. Cashman	Synthetic compounds and methods to decrease nicotine self-administration
AR082799A1 (es)	2010-09-08	2013-01-09	Ucb Pharma Sa	Derivados de quinolina y quinoxalina como inhibidores de quinasa
US9670212B2 (en)	2010-09-14	2017-06-06	Exelixis, Inc.	Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012054332A1 (en)	2010-10-18	2012-04-26	Millennium Pharmaceuticals, Inc.	Substituted hydroxamic acids and uses thereof
JP2013540145A (ja)	2010-10-21	2013-10-31	ウニベルシテートデスザールランデス	コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
MX2013005005A (es)	2010-11-04	2013-10-25	Amgen Inc	Derivados de ciano-4,6-diaminopirimidina o 6-aminopurina como inhibidores de pi3k-delta.
US8901133B2 (en)	2010-11-10	2014-12-02	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2640367A2 (en)	2010-11-15	2013-09-25	Exelixis, Inc.	Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068096A2 (en)	2010-11-15	2012-05-24	Exelixis, Inc.	Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US20140378436A9 (en)	2010-11-24	2014-12-25	Exelixis, Inc.	Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
BR112013012953A2 (pt)	2010-11-24	2019-09-24	Exelixis Inc	benzoxazepinas asn inhibidoras de p13k/m tor e métodos de seu uso e fabricação
AU2011343039B2 (en)	2010-12-14	2017-03-02	Electrophoretics Limited	Casein kinase 1delta (CK1delta) inhibitors
US8765978B2 (en)	2010-12-16	2014-07-01	Transitions Optical, Inc.	Method of making indeno-fused naphthol materials
US8987271B2 (en)	2010-12-22	2015-03-24	Eutropics Pharmaceuticals, Inc.	2,2′-biphenazine compounds and methods useful for treating disease
CN103648499B (zh)	2011-01-10	2017-02-15	无限药品股份有限公司	用于制备异喹啉酮的方法及异喹啉酮的固体形式
TW201242971A (en)	2011-02-25	2012-11-01	Takeda Pharmaceutical	N-substituted oxazinopteridines and oxazinopteridinones
WO2012121953A1 (en)	2011-03-08	2012-09-13	The Trustees Of Columbia University In The City Of New York	Methods and pharmaceutical compositions for treating lymphoid malignancy
SG193337A1 (en)	2011-03-11	2013-10-30	Gilead Calistoga Llc	Combination therapies for hematologic malignancies
EP2685821A4 (en)	2011-03-15	2014-08-20	Abbvie Inc	MODULATORS OF NUCLEAR HORMONAL RECEPTORS
WO2012129562A2 (en)	2011-03-24	2012-09-27	The Scripps Research Institute	Compounds and methods for inducing chondrogenesis
CN102731492B (zh)	2011-03-30	2016-06-29	江苏恒瑞医药股份有限公司	环己烷类衍生物、其制备方法及其在医药上的应用
EP2694071B1 (en)	2011-04-01	2017-01-04	Genentech, Inc.	Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
JO3733B1 (ar)	2011-04-05	2021-01-31	Bayer Ip Gmbh	استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
KR101644051B1 (ko)	2011-05-20	2016-08-01	삼성전자 주식회사	광전자 소자 및 적층 구조
PE20141381A1 (es)	2011-07-01	2014-10-21	Novartis Ag	Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
HK1198443A1 (en)	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
AU2012284091B2 (en)	2011-07-19	2015-11-12	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
BR112014001798B1 (pt)	2011-07-26	2021-07-27	Kbp Biosciences Co., Ltd.	Compostos de tetraciclina 9-aminometila substituídos, seu uso e composição farmacêutica
WO2013013504A1 (zh)	2011-07-26	2013-01-31	山东亨利医药科技有限责任公司	替加环素衍生物
AU2012295280A1 (en)	2011-08-12	2014-03-27	Salk Institute For Biological Studies	Neuroprotective polyphenol analogs
EP2751093A1 (en)	2011-08-29	2014-07-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013066483A1 (en)	2011-08-31	2013-05-10	Novartis Ag	Synergistic combinations of pi3k- and mek-inhibitors
WO2013044169A1 (en)	2011-09-21	2013-03-28	Nestec S.A.	Methods for determining combination therapy with il-2 for the treatment of cancer
KR102258778B1 (ko)	2011-10-19	2021-06-02	파마싸이클릭스 엘엘씨	브루톤 티로신 인산화효소(btk)의 억제제의 용도
WO2013074583A1 (en)	2011-11-14	2013-05-23	The Broad Institute, Inc.	Treatment and prognosis of lymphangioleiomyomatosis
WO2013086131A1 (en)	2011-12-06	2013-06-13	The Trustees Of The University Of Pennsylvania	Inhibitors targeting drug-resistant influenza a
US8772541B2 (en)	2011-12-15	2014-07-08	University of Pittsburgh—of the Commonwealth System of Higher Education	Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
WO2013090725A1 (en)	2011-12-15	2013-06-20	Philadelphia Health & Education Corporation	NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF
AR092790A1 (es)	2012-02-01	2015-05-06	Euro Celtique Sa	Derivados bencimidazolicos del acido hidroxamico
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN104582732A (zh)	2012-06-15	2015-04-29	布里格姆及妇女医院股份有限公司	治疗癌症的组合物及其制造方法
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP3550031A1 (en)	2012-07-24	2019-10-09	Pharmacyclics, LLC	Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US8673972B2 (en)	2012-08-03	2014-03-18	Foundation Medicine, Inc.	Human papilloma virus as predictor of cancer prognosis
WO2014046617A1 (en)	2012-09-19	2014-03-27	Agency For Science, Technology And Research	Compositions and methods for treating cancer
US20150283142A1 (en)	2013-03-15	2015-10-08	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
SI2914296T2 (sl)	2012-11-01	2022-01-31	Infinity Pharmaceuticals, Inc.	Zdravljenje raznih vrst raka z uporabo modulatorjev izooblik PI3-kinaze
US20140120060A1 (en)	2012-11-01	2014-05-01	Infinity Pharmaceuticals, Inc.	Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
US20140120083A1 (en)	2012-11-01	2014-05-01	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
BR112015009879A8 (pt)	2012-11-02	2019-09-17	Lab Francais Du Fractionnement	método in vitro de inibição da proliferação de uma população de células, composto, kit e composição farmacêutica
JP6434416B2 (ja)	2012-11-08	2018-12-05	ライゼン・ファーマシューティカルズ・エスアー	ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
CN104918940B (zh)	2012-11-16	2017-03-08	默沙东公司	人磷脂酰肌醇3‑激酶δ的嘌呤抑制剂
WO2014124458A1 (en)	2013-02-11	2014-08-14	The Regents Of The University Of California	Compositions and methods for treating neurodegenerative diseases
EP2968472A1 (en)	2013-03-15	2016-01-20	Université de Genève	Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
WO2014151386A1 (en)	2013-03-15	2014-09-25	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2908375A1 (en)	2013-04-08	2014-10-16	Pharmacyclics Llc	Ibrutinib combination therapy
JP6227889B2 (ja)	2013-04-23	2017-11-08	関東化學株式会社	新規な有機金属錯体およびアミン化合物の製造方法
RU2705204C2 (ru)	2013-05-30	2019-11-06	Инфинити Фармасьютикалз, Инк.	Лечение злокачественных опухолей с использованием модуляторов изоформ piз-киназы
EP3632208A1 (en)	2013-06-13	2020-04-08	Biomatrica, INC.	Cell stabilization
EA028319B1 (ru)	2013-06-14	2017-11-30	Джилид Калистога Ллс	Ингибиторы фосфатидилинозитол-3-киназы
ES2844200T3 (es)	2013-06-20	2021-07-21	Taiho Pharmaceutical Co Ltd	Método para predecir la eficacia terapéutica del inhibidor de PI3K/AKT/mTOR basándose en la expresión de PHLDA1 o PIK3C2B
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
US20150065431A1 (en)	2013-08-27	2015-03-05	Northwestern University	Reducing cutaneous scar formation and treating skin conditions
AU2014319921A1 (en)	2013-09-11	2016-03-17	Compugen Ltd.	Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
US10111897B2 (en)	2013-10-03	2018-10-30	Duke University	Compositions and methods for treating cancer with JAK2 activity
TWI657085B (zh)	2013-10-04	2019-04-21	英菲尼提製藥股份有限公司	雜環化合物及其用途
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP6626437B2 (ja)	2013-10-08	2019-12-25	アセチロンファーマシューティカルズインコーポレイテッドＡｃｅｔｙｌｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
JP6584391B2 (ja)	2013-10-10	2019-10-02	アセチロンファーマシューティカルズインコーポレイテッドＡｃｅｔｙｌｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
EP3074016A2 (en)	2013-11-26	2016-10-05	Gilead Sciences, Inc.	Therapies for treating myeloproliferative disorders
KR20160093062A (ko)	2013-12-05	2016-08-05	아세르타 파마. 비.브이.	Pi3k 억제제 및 btk 억제제의 치료적 조합
WO2015095834A2 (en)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2015095840A1 (en)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of cdk and erk inhibitors
US11007183B2 (en)	2013-12-20	2021-05-18	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors
WO2015095831A1 (en)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of mtor and erk inhibitors
EP3082779B1 (en)	2013-12-20	2023-06-07	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2015095842A2 (en)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015095838A2 (en)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of mek type i and erk inhibitors
CA3240745A1 (en)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatment using combinations of erk and raf inhibitors
WO2015095807A1 (en)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of egfr and erk inhibitors
EP3102238A1 (en)	2014-01-20	2016-12-14	Gilead Sciences, Inc.	Therapies for treating cancers
US9775844B2 (en)	2014-03-19	2017-10-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CR20210097A (es)	2014-03-21	2022-04-27	Abbvie Inc	Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2015160986A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2015175966A1 (en)	2014-05-16	2015-11-19	Memorial Sloan Kettering Cancer Center	Platelet-derived growth factor receptor mutations and compositions and methods relating thereto
WO2015179772A1 (en)	2014-05-23	2015-11-26	Concert Pharmaceuticals, Inc.	Deuterated phenylquinazolinone and phenylisoquinolinone compounds
KR20170010369A (ko)	2014-05-27	2017-01-31	알미랄, 에스.에이.	병용물
AU2015269197B2 (en)	2014-06-06	2018-10-04	2Seventy Bio, Inc.	Improved T cell compositions
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3662903A3 (en)	2014-10-03	2020-10-14	Novartis AG	Combination therapies
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法

2012
- 2012-01-10 CN CN201280012635.2A patent/CN103648499B/zh active Active
- 2012-01-10 TW TW105115089A patent/TWI659956B/zh active
- 2012-01-10 KR KR1020137021000A patent/KR101875720B1/ko active Active
- 2012-01-10 JP JP2013548626A patent/JP2014501790A/ja not_active Withdrawn
- 2012-01-10 US US13/347,423 patent/US8809349B2/en not_active Ceased
- 2012-01-10 EP EP12734039.6A patent/EP2663309B1/en active Active
- 2012-01-10 TW TW101100966A patent/TWI546305B/zh active
- 2012-01-10 UA UAA201309964A patent/UA115767C2/uk unknown
- 2012-01-10 BR BR112013017670-9A patent/BR112013017670B1/pt active IP Right Grant
- 2012-01-10 MX MX2013008065A patent/MX347708B/es active IP Right Grant
- 2012-01-10 CA CA2824197A patent/CA2824197C/en active Active
- 2012-01-10 KR KR1020187018781A patent/KR20180080358A/ko not_active Ceased
- 2012-01-10 NZ NZ612909A patent/NZ612909A/en unknown
- 2012-01-10 TW TW107124155A patent/TWI674262B/zh active
- 2012-01-10 AU AU2012205669A patent/AU2012205669B2/en active Active
- 2012-01-10 AR ARP120100083A patent/AR084824A1/es unknown
- 2012-01-10 SG SG2013052568A patent/SG191897A1/en unknown
- 2012-01-10 EP EP19161632.5A patent/EP3581574A1/en not_active Withdrawn
- 2012-01-10 EP EP17160958.9A patent/EP3238722B1/en active Active
- 2012-01-10 PE PE2017002336A patent/PE20180318A1/es unknown
- 2012-01-10 SG SG10201600179RA patent/SG10201600179RA/en unknown
- 2012-01-10 WO PCT/US2012/020831 patent/WO2012097000A1/en not_active Ceased
- 2012-01-10 ES ES12734039.6T patent/ES2637113T3/es active Active
- 2012-01-10 DK DK12734039.6T patent/DK2663309T3/en active
- 2012-01-10 PE PE2013001545A patent/PE20141303A1/es active IP Right Grant
- 2012-01-10 PH PH1/2013/501465A patent/PH12013501465A1/en unknown
2013
- 2013-07-09 CL CL2013002007A patent/CL2013002007A1/es unknown
- 2013-07-09 ZA ZA2013/05150A patent/ZA201305150B/en unknown
- 2013-07-09 IL IL227387A patent/IL227387B/en active IP Right Grant
2014
- 2014-07-09 US US14/327,499 patent/US9290497B2/en active Active
2016
- 2016-02-04 US US15/016,117 patent/US9840505B2/en active Active
- 2016-02-23 US US15/051,529 patent/USRE46621E1/en active Active
- 2016-11-30 JP JP2016232909A patent/JP6454672B2/ja active Active
2017
- 2017-10-31 US US15/799,612 patent/US10550122B2/en active Active
2018
- 2018-04-09 HK HK18104605.9A patent/HK1245110B/en unknown
- 2018-05-03 PH PH12018500960A patent/PH12018500960A1/en unknown
2020
- 2020-01-03 US US16/734,135 patent/US11312718B2/en active Active
2022
- 2022-03-21 US US17/699,582 patent/US20230108157A1/en not_active Abandoned
2024
- 2024-07-03 US US18/763,528 patent/US20250197400A1/en active Pending

Also Published As

Publication number	Publication date
TW201247670A (en)	2012-12-01
IL227387A0 (en)	2013-09-30
RU2013137424A (ru)	2015-02-20
JP6454672B2 (ja)	2019-01-16
EP3238722B1 (en)	2019-03-13
MX347708B (es)	2017-05-09
US20120184568A1 (en)	2012-07-19
USRE46621E1 (en)	2017-12-05
EP3238722A1 (en)	2017-11-01
IL227387B (en)	2018-07-31
CA2824197A1 (en)	2012-07-19
US9290497B2 (en)	2016-03-22
KR20180080358A (ko)	2018-07-11
EP3581574A1 (en)	2019-12-18
US10550122B2 (en)	2020-02-04
CN103648499B (zh)	2017-02-15
EP2663309A1 (en)	2013-11-20
PE20141303A1 (es)	2014-10-01
US20160152619A1 (en)	2016-06-02
EP2663309B1 (en)	2017-03-15
ZA201305150B (en)	2014-09-25
US9840505B2 (en)	2017-12-12
NZ612909A (en)	2015-09-25
KR20140020249A (ko)	2014-02-18
SG191897A1 (en)	2013-08-30
PE20180318A1 (es)	2018-02-09
MX2013008065A (es)	2014-01-31
EP2663309A4 (en)	2014-06-18
US20140371450A1 (en)	2014-12-18
US8809349B2 (en)	2014-08-19
JP2017061547A (ja)	2017-03-30
US20230108157A1 (en)	2023-04-06
KR101875720B1 (ko)	2018-07-09
TW201700475A (zh)	2017-01-01
UA115767C2 (uk)	2017-12-26
CA2824197C (en)	2020-02-25
US20250197400A1 (en)	2025-06-19
US20180273535A1 (en)	2018-09-27
ES2637113T3 (es)	2017-10-10
AU2012205669B2 (en)	2015-08-20
AU2012205669A1 (en)	2013-05-02
TWI659956B (zh)	2019-05-21
TWI674262B (zh)	2019-10-11
RU2626883C2 (ru)	2017-08-02
BR112013017670B1 (pt)	2022-07-19
WO2012097000A1 (en)	2012-07-19
CN103648499A (zh)	2014-03-19
SG10201600179RA (en)	2016-02-26
AR084824A1 (es)	2013-06-26
HK1245110B (en)	2020-04-24
DK2663309T3 (en)	2017-06-19
TWI546305B (zh)	2016-08-21
JP2014501790A (ja)	2014-01-23
BR112013017670A2 (es)	2017-08-15
PH12013501465A1 (en)	2013-09-09
PH12018500960A1 (en)	2019-03-04
US20200385388A1 (en)	2020-12-10
US11312718B2 (en)	2022-04-26
TW201906841A (zh)	2019-02-16

Publication	Publication Date	Title
CL2013002007A1 (es)	2014-04-11	Compuesto polimorfo (s)-3-(1-(9h-purin-6-ilamino)etil)-8-cloro-2-fenilisoquinolin-1-(2h)-ona de formas b-j, amorfa, sal, solvato o hidrato del mismo; mezclas de estos compuestos; metodo para preparar el polimorfo de forma c; composicion farmaceutica; metodo de tratamiento; uso para el tratamiento de un trastorno mediado por pi3k.
PH12019501321B1 (en)	2020-10-12	Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
CL2015001442A1 (es)	2015-08-28	Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.
PH12016502382A1 (en)	2017-02-20	Substituted indazole compounds as irak4 inhibitors
IL258772B (en)	2021-01-31	Jak kinase inhibitory compounds for the treatment of respiratory disease
ZA201700737B (en)	2019-04-24	Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
CL2013003051A1 (es)	2014-07-11	Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CR20140413A (es)	2014-11-05	Inhibidores de serina/treonina cinasa
CR20160098A (es)	2016-07-11	Polimorfo de los inhibidores de la syk
GEP20186921B (en)	2018-11-12	Pyrazolopyridines and pyrazolopyrimidines
DK3699181T3 (da)	2023-03-20	Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
BR112014010183A2 (pt)	2017-05-02	composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase
CL2014001049A1 (es)	2014-10-24	Compuestos derivados de purina sustituida, inhibidores de mtor; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento o prevencion del cancer, un trastorno neurodegenerativo o una enfermedad oftalmologica.
CL2013002820A1 (es)	2014-04-11	Compuestos derivados de cefalosporinas, un profarmaco, un hidrato, un solvato, un isomero o una sal; composiciones farmaceuticas de estos; y un metodo para un tratamiento antibiotico.
GB2503852B (en)	2018-12-12	Compounds for the treatment of neuropsychiatric disorders
CR20150114A (es)	2015-05-11	Composición farmacéutica recubierta que contiene regorafenib
CL2014000543A1 (es)	2014-09-26	Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2013003686A1 (es)	2014-08-29	Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña.
AR100095A1 (es)	2016-09-07	Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
NI201600134A (es)	2017-03-13	Compuestos químicos
TN2014000135A1 (en)	2015-07-01	Substituted pyrazole analogues as rar antagonists
BR112013015903A2 (pt)	2018-06-05	polimorfo cristalino, processo para preparar um polimorfo, composição farmacêutica, forma purificada do polimorfo, uso de um polimorfo, processo para preparar um composto, e, composto.
CL2011000120A1 (es)	2011-06-24	Proceso de preparacion de compuestos 2-amino-tiazolonas sustituidas.
AR117467A2 (es)	2021-08-11	Procesos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
HK1192448A (en)	2014-08-22	Compounds for use in the treatment of feline retroviral infections